ライフサイエンスコーパス: hypoglycaemic

1 (2.1 vs. 3.0 micromol ml(-1), P < 0.05) and hypoglycaemic (0.90 vs. 1.31 micromol ml(-1), P < 0.002)

2 sodes (18 CGM and 21 control) and time spent hypoglycaemic (3% vs 4%; p=0.10).

3 (2 mU (kg fat-free mass (FFM))(-1) min(-1)), hypoglycaemic (3.33 mmol l(-1)) clamps 1 week apart, ran

4 In addition, quince DFs exhibited in vitro hypoglycaemic activity, exhibiting high glucose adsorpti

5 Conventional oral hypoglycaemic agents do not target, or adequately contro

6 hy, agriculture occupation, those under oral hypoglycaemic agents or insulin or both as compared to t

7 Oral hypoglycaemic agents, principally metformin and glibencl

8 first in the thiazolidinedione class of oral hypoglycaemic agents, was launched in the USA in March,

9 ssant, anxiolytic, antihypertensive and oral hypoglycaemic agents-as well as evidence of laboratory a

10 Hypoglycaemic and lipid-lowering therapies may have a ro

11 ic steatohepatitis (NASH) and the effects of hypoglycaemic and lipid-lowering therapies on NAFLD/NASH

12 -low feature reduced the frequency of sensor hypoglycaemic and severe hypoglycaemic events in hypogly

13 IUGR fetuses are both hypoxic and hypoglycaemic, and have reduced insulin and insulin-like

14 t (ABP) has various bioactive compounds with hypoglycaemic, antioxidant and anti-inflammatory activit

15 3 +/- 0.5 mmHg; n = 8), glucose (chronically hypoglycaemic; blood glucose, 0.49 +/- 0.03 mmol l(-1);

16 linaemic hypoglycaemia is essential to avoid hypoglycaemic brain injury, especially in the vulnerable

17 At each age, HPA axis function was tested by hypoglycaemic challenge (I.V. insulin; 0.5 IU (kg body w

18 hy alpha-cells are electrically active under hypoglycaemic conditions and generate large Na(+) - and

19 se of hyperglycaemia changes the response to hypoglycaemic drugs; HNF-1alpha diabetes has marked sulp

20 intestinal DNJ concentration and prolong the hypoglycaemic effect in vivo.

21 omics and metabolomic studies found that the hypoglycaemic effect of BBR is mediated by the inhibitio

22 hese compounds in vivo antagonises insulin's hypoglycaemic effect.

23 l and 3 h time points indicating a prolonged hypoglycaemic effect.

24 gene have been described as sensitive to the hypoglycaemic effects of sulphonylureas.

25 RD peels exhibited the best hypoglycaemic effects, while Annurca flesh appeared the

26 n oral insulin formulations as well as their hypoglycaemic effects.

27 th exenatide and a sulphonylurea had a major hypoglycaemic episode.

28 7,898 admissions, the triggers identified 71 hypoglycaemic episodes at a cut-off of 3.3 mmol/l.

29 We noted no severe hypoglycaemic episodes during the control period compare

30 Fewer hypoglycaemic episodes occurred in the stepwise group th

31 r reductions in HbA1c and weight, with fewer hypoglycaemic episodes, and was well tolerated, with a s

32 may be negated by the increased frequency of hypoglycaemic episodes, which may aggravate neurological

33 longside weight loss and a minimum number of hypoglycaemic episodes.

34 ry, the treatment must account for potential hypoglycaemic episodes.

35 frailty and withdrawal, adverse events, and hypoglycaemic episodes.

36 One severe hypoglycaemic event occurred in the advanced hybrid clos

37 nts who received ketogenic feeding had fewer hypoglycaemic events (0.0% vs. 1.6%), required less exog

38 CI -3.5 to -2.3]; p<0.0001) and fewer severe hypoglycaemic events (instances requiring third-party as

39 r day for alefacept; p=0.02) and the rate of hypoglycaemic events (mean of 10.9 events per person per

40 GB operation and a high risk of postprandial hypoglycaemic events have lower levels of betatrophin.

41 frequency of sensor hypoglycaemic and severe hypoglycaemic events in hypoglycaemia-prone adults compa

42 r renal impairment; and more than two severe hypoglycaemic events in the past year.

43 e and prone study periods, and there were no hypoglycaemic events in the prone study period.

44 tive association was followed by significant hypoglycaemic events in the RYGB group.

45 in and had fewer mild-to-moderate and severe hypoglycaemic events on inhaled insulin plus insulin gla

46 The frequency of hypoglycaemic events per month was similar between the g

47 e intervention group had significantly fewer hypoglycaemic events per participant per week (1.1 [SD 1

48 The number of confirmed hypoglycaemic events per patient year was 1.8 for IDegLi

49 Severe or blood glucose-confirmed hypoglycaemic events were reported in four patients on s

50 Treatment-emergent hypoglycaemic events were similar in the TAK-875 and pla

51 in the 4 h C-peptide AUC, insulin use, major hypoglycaemic events, and HbA1c concentrations.

52 th RYGB and exaggerated risk of postprandial hypoglycaemic events, basal and dynamic betatrophin leve

53 rimary outcome was the mean number of sensor hypoglycaemic events, defined as 55 mg/dL (3.1 mmol/L) o

54 sociated with lower HbA1c and a reduction in hypoglycaemic events, promoting overall health and athle

55 eptide AUC, lowered insulin use, and reduced hypoglycaemic events, suggesting efficacy.

56 Safety was assessed by the frequency of hypoglycaemic events.

57 of hypoglycaemia and the risk of subsequent hypoglycaemic events.

58 term morbidity and mortality associated with hypoglycaemic events.

59 have demonstrated the risks associated with hypoglycaemic events.

60 aemic for 14 days, and in a subset of 14-day hypoglycaemic fetuses returned to euglycaemia for 5 days

61 uglycaemic (E) control fetuses, fetuses made hypoglycaemic for 14 days, and in a subset of 14-day hyp

62 mass index with a stepped hyperinsulinaemic hypoglycaemic glucose clamp.

63 y was to measure beta-cell responsiveness in hypoglycaemic (H) fetal sheep and ascertain whether a 5

64 igher insulin dose than needed can lead to a hypoglycaemic incidence, which can be anything from unco

65 ated that LY393615 protected against hypoxia-hypoglycaemic insults in brain slices and also provided

66 y of care received compared with patients on hypoglycaemic medication.

67 ee distinct sources to identify non diabetic hypoglycaemic patients: bedside and laboratory blood glu

68 acity (ORAC, FRAP and ABTS) and the in vitro hypoglycaemic potential via inhibition of alpha-amylase

69 bolus insulin dose, and with no increase in hypoglycaemic rates compared with once-daily glargine U1

70 in vivo is demonstrated, providing emergency hypoglycaemic rescue in diabetic mice.

71 Since the hypoglycaemic response was blocked on co-infusion with t

72 taurocholate, this was followed by a marked hypoglycaemic response which was specific to the ileum a

73 -Phe-cholyl-insulin did cause a long lasting hypoglycaemic response, indicating that absorption had o

74 oth were biologically active as indicated by hypoglycaemic responses on systemic injection, though th

75 onstrates improved glycaemic control and low hypoglycaemic risk in diabetic patients.

76 od glucose levels with reduced potential for hypoglycaemic risk in patients with type II diabetes mel

77 ained dogs reliably respond to their owners' hypoglycaemic state, and whether owners experience facil

78 In this hypermetabolic, hypoglycaemic state, propranolol stimulated a rise in P

79 that some pet dogs respond to their owners' hypoglycaemic state.

80 rofound inhibitory effect of insulin-induced hypoglycaemic stress on pulsatile LH release.

81 le for this brainstem structure in mediating hypoglycaemic stress-induced suppression of the hypothal

82 ses for diabetes change the response to oral hypoglycaemic therapy.

83 oncentrations, but RagA(GTP/GTP) mice remain hypoglycaemic until death, despite using glycogen at a f

84 case in which the person is recognized being hypoglycaemic with the blood dextrose level falling down